companies / nanophoria-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-02 json
| total_raised | 90,180,00090.2M | ○ |
|---|---|---|
| founded | null | |
| hq | Modena | |
| industry | unknown | |
| stage | series-a |
NanoPhoria develops nanoparticle drug-delivery technology for inhaled treatments in respiratory and ophthalmic disease. It serves pharma partners reformulating biologics and small molecules as inhalable products. Its lipid-nanoparticle platform crosses the lung-tissue barriers where existing dry-powder inhaler tech leaves a deposition gap.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-10-01 | series-a | 90,180,00090.2M | null | ○ |
bootstrap, jquery 1.11.1, jquery cdn, jquery migrate 3.4.1, mysql, nginx, parallax.js, php, plesk, wordpress 7.0
| fact | status | src |
|---|---|---|
| Series A, $90.2M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |